CO7240357A2 - Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal - Google Patents

Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal

Info

Publication number
CO7240357A2
CO7240357A2 CO15015754A CO15015754A CO7240357A2 CO 7240357 A2 CO7240357 A2 CO 7240357A2 CO 15015754 A CO15015754 A CO 15015754A CO 15015754 A CO15015754 A CO 15015754A CO 7240357 A2 CO7240357 A2 CO 7240357A2
Authority
CO
Colombia
Prior art keywords
solution
spine
administration
acetaminophen
injectable
Prior art date
Application number
CO15015754A
Other languages
English (en)
Spanish (es)
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sint Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7240357(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sint Sa filed Critical Sint Sa
Publication of CO7240357A2 publication Critical patent/CO7240357A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO15015754A 2012-06-29 2015-01-27 Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal CO7240357A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale

Publications (1)

Publication Number Publication Date
CO7240357A2 true CO7240357A2 (es) 2015-04-17

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15015754A CO7240357A2 (es) 2012-06-29 2015-01-27 Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal

Country Status (44)

Country Link
US (2) US11344517B2 (enExample)
EP (1) EP2874602B1 (enExample)
JP (1) JP5876620B2 (enExample)
KR (1) KR102118227B1 (enExample)
CN (1) CN104487051B (enExample)
AP (1) AP2014008152A0 (enExample)
AR (1) AR091633A1 (enExample)
AU (1) AU2013282753B2 (enExample)
BR (1) BR112014032818B1 (enExample)
CA (1) CA2876801C (enExample)
CL (1) CL2014003536A1 (enExample)
CO (1) CO7240357A2 (enExample)
CR (1) CR20150036A (enExample)
CU (1) CU20140150A7 (enExample)
CY (1) CY1117691T1 (enExample)
DK (1) DK2874602T3 (enExample)
DO (1) DOP2014000302A (enExample)
EA (1) EA028909B1 (enExample)
EC (1) ECSP15000500A (enExample)
ES (1) ES2578012T3 (enExample)
GE (1) GEP201706689B (enExample)
HR (1) HRP20160706T1 (enExample)
HU (1) HUE029431T2 (enExample)
IL (1) IL236423A (enExample)
IT (1) ITMI20121154A1 (enExample)
MA (1) MA37811B1 (enExample)
MD (1) MD4537C1 (enExample)
ME (1) ME02431B (enExample)
MX (1) MX369264B (enExample)
MY (1) MY169251A (enExample)
NI (1) NI201400147A (enExample)
NZ (1) NZ703829A (enExample)
PE (1) PE20150331A1 (enExample)
PH (1) PH12015500178B1 (enExample)
PL (1) PL2874602T3 (enExample)
PT (1) PT2874602T (enExample)
RS (1) RS54844B1 (enExample)
SG (2) SG11201408479WA (enExample)
SI (1) SI2874602T1 (enExample)
SM (1) SMT201600248B (enExample)
TN (1) TN2014000526A1 (enExample)
UA (1) UA117101C2 (enExample)
WO (1) WO2014002042A1 (enExample)
ZA (1) ZA201409478B (enExample)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427728T2 (de) * 1993-04-14 2002-05-08 Nippon Sanso Corp., Tokio/Tokyo Vorrichtung zur herabsetzung vom gelöstem sauerstoff
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
US20050203175A1 (en) * 2001-12-18 2005-09-15 Ioulia Tseti Parenteral composition of paracetamol
FR2851164B1 (fr) * 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
RU2419421C2 (ru) * 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
JP5909750B2 (ja) * 2007-11-13 2016-04-27 マリンクロット アイピー 低用量静脈内アセトアミノフェン
WO2009098716A2 (en) 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Stable pharmaceutical aqueous compositions
WO2009143558A1 (en) 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
PT2588097T (pt) * 2010-06-30 2021-05-25 Troikaa Pharmaceuticals Ltd Composições farmacêuticas que compreendem paracetamol e processo para preparar as mesmas

Also Published As

Publication number Publication date
AR091633A1 (es) 2015-02-18
EA201500065A1 (ru) 2015-10-30
MD20140138A2 (ro) 2015-06-30
ME02431B (me) 2016-09-20
US20150148379A1 (en) 2015-05-28
DOP2014000302A (es) 2015-03-15
EA028909B1 (ru) 2018-01-31
SMT201600248B (it) 2016-08-31
PH12015500178A1 (en) 2015-04-06
CU20140150A7 (es) 2015-10-27
CN104487051B (zh) 2017-12-12
CA2876801A1 (en) 2014-01-03
AU2013282753B2 (en) 2017-03-02
SI2874602T1 (sl) 2016-09-30
IL236423A0 (en) 2015-02-26
MD4537B1 (ro) 2017-12-31
US11344517B2 (en) 2022-05-31
PE20150331A1 (es) 2015-03-07
JP5876620B2 (ja) 2016-03-02
AU2013282753A1 (en) 2015-02-05
SG10201704482YA (en) 2017-07-28
US20160128955A1 (en) 2016-05-12
BR112014032818B1 (pt) 2022-06-14
EP2874602B1 (en) 2016-03-30
MD4537C1 (ro) 2018-07-31
MY169251A (en) 2019-03-19
UA117101C2 (uk) 2018-06-25
PH12015500178B1 (en) 2021-08-04
CR20150036A (es) 2015-03-13
MA37811B1 (fr) 2017-07-31
TN2014000526A1 (en) 2016-03-30
HUE029431T2 (en) 2017-03-28
PT2874602T (pt) 2016-07-13
ES2578012T3 (es) 2016-07-20
MA37811A1 (fr) 2016-10-31
CL2014003536A1 (es) 2015-05-08
KR102118227B1 (ko) 2020-06-03
MX2014015402A (es) 2015-06-17
EP2874602A1 (en) 2015-05-27
SG11201408479WA (en) 2015-01-29
IL236423A (en) 2017-07-31
GEP201706689B (en) 2017-06-26
RS54844B1 (sr) 2016-10-31
DK2874602T3 (en) 2016-07-04
ITMI20121154A1 (it) 2013-12-30
CY1117691T1 (el) 2017-05-17
PL2874602T3 (pl) 2016-10-31
AP2014008152A0 (en) 2014-12-31
CN104487051A (zh) 2015-04-01
ECSP15000500A (es) 2015-11-30
ZA201409478B (en) 2016-01-27
NZ703829A (en) 2016-06-24
HRP20160706T1 (hr) 2016-08-12
JP2015522004A (ja) 2015-08-03
KR20150027160A (ko) 2015-03-11
WO2014002042A1 (en) 2014-01-03
NI201400147A (es) 2015-04-13
MX369264B (es) 2019-11-04
BR112014032818A2 (pt) 2017-06-27
CA2876801C (en) 2020-11-03

Similar Documents

Publication Publication Date Title
EA201590058A1 (ru) Аналоги глюкагона
BR112015026325A2 (pt) dosagem oral de compostos glp-1
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
AR098738A1 (es) Análogos del péptido exendina-4 no acilados
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
UA115811C2 (uk) Стабільний розчин об'єднаних баклофену, сорбіту і налтрексону для перорального застосування
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
EA201690183A1 (ru) Замещенные пиразолопиридинамины
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2016000397A1 (es) Tratamiento contra el cáncer
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
DOP2014000302A (es) Solucion de acetaminofen supersaturada inyectable para la administracion por la espina dorsal
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
BR112015030751A2 (pt) formas polimórficas de icotinib e usos das mesmas
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto